Vima Therapeutics
Vima Therapeutics raises $60M Series A at $280M valuation
Vima Therapeutics: Series A Funding Round
Vima Therapeutics has successfully raised $60M in Series A funding, reaching a valuation of $280M.
Company Overview
Focused on oral therapies for movement disorders
Funding Details
The Series A round was led by Third Rock Ventures, with participation from Arch Venture Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2023
- Employees: 50+
- Category: Biotech
Investment
Vima Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Series A
- Arch Venture Partners: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free